Sarepta Therapeutics: A Stock Divided by Extreme Analyst Views

Sarepta Therapeutics shares advanced 3.6% to $18.72 in the latest trading session, yet this modest gain conceals a deeply fractured analyst landscape. Market experts display unprecedented divergence in their assessments, with price targets ranging from a pessimistic $12 to an optimistic $150—a spread that highlights the extraordinary uncertainty surrounding the biopharmaceutical company.

The average price target of $39.32 suggests potential upside exceeding 100%, but the extreme dispersion of opinions tells a more complex story. Among the 29 analysts covering the company, investment recommendations reveal significant caution: six advocate selling positions, fourteen recommend holding, while only nine endorse buying.

Recent analyst actions underscore this division. BMO Capital initiated coverage with an “Outperform” rating and a $50 target, while Wells Fargo raised its expectation to the same... Read more...